a) monoglyceride preparations having at least 80 % monoglyceride content and having a formula



wherein R_1 and R_2 is H, and R_3 is one acyl group containing from 6 to 24 carbon atoms, and where the acyl chains may contain one or more unsaturated bonds together with one or more substances selected from the group consisting of:

b) fatty acids with 6 to 24 carbon atoms, wherein the acyl chain may contain one or more unsaturated bonds,

and wherein the percentage of monoglyceride a) in fatty acid b0 is between 10 and 90%.

40. The adjuvant composition according to Claim 39, wherein the monoglyceride preparation content is at least 90 %.

41. The adjuvant composition according to Claim 39, wherein the monoglyceride preparation content is at least 95%.

42. The adjuvant composition according to Claim 39, wherein the acyl chains of the monoglyceride preparations contain 8 to 20 carbon atoms and wherein the acyl chains may contain one or more unsaturated bonds.

43. The adjuvant composition according to Claim 39, wherein the acyl chains of the monoglyceride preparations contain 14 to 20 carbon atoms and wherein the acyl chains may contain one or more unsaturated bonds.

44. The adjuvant composition according to Claim 39, wherein the acyl chains of the fatty acid contain 8 to 20 carbon atoms, preferably 14 to 20 carbon atoms and wherein the acyl chains may contain one or more unsaturated bonds.

45. The adjuvant composition according to Claim 39, wherein the acyl chains of the fatty acid contain 14 to 20 carbon atoms and wherein the acyl chains may contain one or more unsaturated bonds.

46. The adjuvant composition according to Claim 39, wherein the antigen comprises an antigen or vaccine that is selected from the group consisting of antigens and vaccines relevant to humans or animals.

47. The adjuvant composition according to Claim 46, wherein the animals are marine animals.

48. The adjuvant composition according to Claim 39, wherein the composition comprises additional pharmaceutical excipients selected from the group consisting of preservatives and osmotic pressure controlling agents, pH-controlling agents, organic solvents, hydrophobic agents, enzyme inhibitors, water absorbing polymers, surfactants, absorption promoters and anti-oxidative agents.

49. The adjuvant composition according to Claim 39, wherein the composition comprises additional adjuvants.

50. The adjuvant composition according to Claim 39, wherein the composition is in a form suitable for parenteral or mucosal administration.

51. The adjuvant composition according to Claim 50, wherein the composition is in a form suitable for administration to the mucosa of the nose, mouth, vagina, rectum or the intestine.

52. The adjuvant composition according to Claim 50, wherein the composition is in a form suitable for administration to the mucosa of the nose.

53. A vaccine or antigen composition, containing in 100 g of the final composition:

from 0.01 to 90 g of a antigen or vaccine component
from 1 to 20 g of a monoglyceride
from 1 to 20 g of a fatty acid
from 0.01 to 99 g of water
from 0.01 to 99 g of PBS or saline

and optionally one or more additional adjuvant or excipient.

54. A vaccine or antigen composition comprising one or more substances selected from the group consisting of:

a) monoglyceride preparations having at least 80 % monoglyceride content and having a formula:



wherein R_1 and R_2 is H, and R_3 is one acyl group containing from 6 to 24 carbon atoms, and where the acyl chains may contain one or more unsaturated bonds together with one or more substances selected from the group consisting of:

b) fatty acids with 6 to 24 carbon atoms, wherein the acyl chain may contain one or more unsaturated bonds,

and wherein the percentage of monoglyceride a) in fatty acid b0 is between 10 and 90%;

in an amount of 0.01 to 15 g/100 ml of the total volume of the composition, and a vaccine or antigen component that is selected from the group consisting of antigens and vaccines relevant to humans or animals, and optionally one or more additional adjuvant or excipient.

55. The vaccine or antigen composition according to Claim 54, wherein the monoglyceride preparation content is at least 90 %.

56. The vaccine or antigen composition according to Claim 55, wherein the monoglyceride preparation content is at least 95%.

57. The vaccine or antigen composition according to Claim 54, wherein the acyl chains of the monoglyceride preparations contain 8 to 20 carbon atoms, and wherein the acyl chains may contain one or more unsaturated bonds.

58. The vaccine or antigen composition according to Claim 57, wherein the acyl chains of the monoglyceride preparations contain 14 to 20 carbon atoms and where the acyl chains may contain one or more unsaturated bonds.

59. The vaccine or antigen composition according to Claim 54, wherein the acyl chains of the fatty acid contain 8 to 20 carbon atoms and where the acyl chains may contain one or more unsaturated bonds.

60. The vaccine or antigen composition according to Claim 59, wherein the acyl chains of the fatty acid contain 14 to 20 carbon atoms and where the acyl chains may contain one or more unsaturated bonds.

61. The adjuvant composition according to Claim 54, wherein the animals are marine animals.- -